TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00798798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Externally Implantable Tissue Expansion Device
Description: Will Apply Externally Implantable Tissue Expansion Device for 2 Days
Study: NCT01301963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: Given SC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study: NCT03854344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: Injected subcutaneously for skin graft harvesting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Injected subcutaneously for skin graft harvesting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: Used for regional nerve block for skin graft harvesting
Study: NCT02090738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard regimen group
Study: NCT00360971

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: Patients will receive cisplatin (100 mg/m2) administered intravenously on days 1, 22, and 43 of the treatment course.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Four doses of placebo, 180ųg/kg, administered as an i.v. bolus injection over 30-60 seconds. Starting on day -3 (Friday) prior to radiation therapy / chemotherapy and then once weekly, on days 5, 12, and 19.
Study: NCT03498183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIBI-Tc99m/Iodine-123
Description: Following the injection of MIBI-Tc99m/Iodine-123 , the patients will have a scintigraphy.
Study: NCT01525290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: Intravenous tissue plasminogen activator (Alteplase) 0.9 mg/kg body-weight up to a maximum of 90 mg, 10% as bolus, 90% over 1 hour as infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: lyophilised powder to be reconstituted as solution indistinguishable from the active drug
Study: NCT01058200

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iCup
Description: new vacuum extractor: sterile disposable plastic cup
Study: NCT04466696

Intervention type: BEHAVIORAL
Intervention: ERAS protocol
Description: items of ERAS protocol applied
Study: NCT01058200

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: reference cup
Description: reference cup of the obstetrical ward: metallic cup
Study: NCT05717088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24% Sucrose solution
Description: Infants will either receive oral sucrose (24%) 2 minutes before the procedure LUS scan. The dose will be 0.2 mL, 0.5 mL and 1 mL for infants with current weight \< 1500g, 1500-2500g, and \> 2500g respectively.
Study: NCT02619734

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of Autologous Bone Marrow Mononuclear Cells
Description: Autologous bone marrow-derived mononuclear cells will be administered by intramuscular injection into and around the leg ulcer. The number of injected cells will be from 5x108 to 1x109 total number of cells on Study Day 1.
Study: NCT01488799

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing and Cognitive Behavioural Therapy
Description: Participants with a diagnosis of severe Generalized Anxiety Disorder will be randomly assigned to receive either 4 weekly sessions of MI followed by 11 weekly sessions of CBT (MI-CBT arm) or 15 weekly sessions of CBT (CBT alone arm). Both groups will also receive 2 follow-up CBT treatment sessions at 1 and 3 months post-treatment. In order to increase generalizability to clinical practice, in the CBT phase for the MI-CBT arm, therapists will shift to MI in the presence of empirically derived markers of resistance and shift back to CBT when resistance has diminished. In the CBT alone arm therapists will respond to resistance using manualized recommendations derived from leading CBT theorists for the management of resistance.
Study: NCT00559559

Intervention type: DEVICE
Group type: OTHER
Intervention: ICD implant + Patient Notifier turned OFF
Description: ICD implant, plus standard care, i.e. Patient Notifier turned off

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICD Implant + Patient Notifier turned ON
Description: ICD implant. The Patient Notifier™ feature will be turned ON.
Study: NCT01197950

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Acupuncture
Description: The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro Acupuncture
Description: The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour. Eight needles in the painful area (local points) will be connected to an electro-stimulator and stimulated with high frequency (80 Hz) square wave pulses (0.18-ms duration) with alternating polarity. The woman will adjust the intensity of the electrical stimulation to be just under pain threshold.
Study: NCT00731315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-assisted treatment group
Description: This group will receive computer-assisted expedited treatment for uncomplicated UTI or complicated cystitis based on their symptoms and past medical history reported on the computer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-assisted treatment group
Description: This group will receive computer-assisted expedited treatment for uncomplicated UTI or complicated cystitis based on their symptoms and past medical history reported on the computer.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care group
Description: This group will receive usual care for an uncomplicated UTI or complicated cystitis in the Emergency Department or Community Health Center.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care group
Description: This group will receive usual care for an uncomplicated UTI or complicated cystitis in the Emergency Department or Community Health Center.
Study: NCT00941239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin ER
Description: 850mg daily for 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 850 mg daily for 30 days
Study: NCT02308436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Candida Mouthwash with Curolox™ Peptide
Description: Prophylaxis - protection and care of teeth against caries \& acidic challenges
Study: NCT03418844

Intervention type: OTHER
Group type: OTHER
Intervention: Self-questionnaires of living conditions and quality of life
Description: Patients will complete self-questionnaires of living conditions and quality of life (MFI-20, FACT-G/FACT-O, FACT/COG-NTX, FACT-Cog, HADS, Insomnia Severity Index , International Physical Activity Questionnaire)

Intervention type: OTHER
Group type: OTHER
Intervention: Self-questionnaires of living conditions and quality of life
Description: Patients will complete self-questionnaires of living conditions and quality of life (MFI-20, FACT-G/FACT-O, FACT/COG-NTX, FACT-Cog, HADS, Insomnia Severity Index , International Physical Activity Questionnaire)

Intervention type: OTHER
Group type: OTHER
Intervention: Self-questionnaires of living conditions and quality of life
Description: Patients will complete self-questionnaires of living conditions and quality of life (MFI-20, FACT-G/FACT-O, FACT/COG-NTX, FACT-Cog, HADS, Insomnia Severity Index , International Physical Activity Questionnaire)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac, pulmonary, auditory and biological assessment
Description: Patients will perform :~* Cardiac assesments (ECG, Carotid and humeral Doppler ultrasound, Trans-thoracic echocardiography 2D and 3D)~* Pulmonary and auditory assesment ( Respiratory Functional Exploration, Tonal audiogram)~* Blood tests

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac, pulmonary, auditory and biological assessment
Description: Patients will perform :~* Cardiac assesments (ECG, Carotid and humeral Doppler ultrasound, Trans-thoracic echocardiography 2D and 3D)~* Pulmonary and auditory assesment ( Respiratory Functional Exploration, Tonal audiogram)~* Blood tests
Study: NCT01960413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast added to Hydroxyurea
Study: NCT03568526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend a therapy session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT01960413

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo added to Hydroxyurea
Study: NCT01529957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nemonoxacin Malate Sodium Chloride
Description: Nemonoxacin Malate Sodium Chloride,intravenous injection,once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nemonoxacin Malate Sodium Chloride
Description: Nemonoxacin Malate Sodium Chloride,intravenous injection,once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nemonoxacin Malate Sodium Chloride
Description: Nemonoxacin Malate Sodium Chloride,intravenous injection,once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nemonoxacin Malate Sodium Chloride
Description: Nemonoxacin Malate Sodium Chloride,intravenous injection,once daily
Study: NCT02083588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dTMS
Description: All subjects will receive prefrontal deep rTMS of H1 Coil (75 trains of 2 seconds, 20 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold, a total of 3000 pulses per session), for 4 weeks, 5 days a week, overall 20 sessions.
Study: NCT01529957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nemonoxacin Malate Sodium Chloride
Description: Nemonoxacin Malate Sodium Chloride,intravenous injection,once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nemonoxacin Malate Sodium Chloride
Description: Nemonoxacin Malate Sodium Chloride,intravenous injection,once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nemonoxacin Malate Sodium Chloride
Description: Nemonoxacin Malate Sodium Chloride,intravenous injection,once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nemonoxacin Malate Sodium Chloride
Description: Nemonoxacin Malate Sodium Chloride,intravenous injection,once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nemonoxacin Malate Sodium Chloride
Description: Nemonoxacin Malate Sodium Chloride,intravenous injection,once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nemonoxacin Malate Sodium Chloride
Description: Nemonoxacin Malate Sodium Chloride,intravenous injection,once daily
Study: NCT00360971

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neck dissection
Description: A neck dissection is required for patients with persistent nodal disease, any stage, if a palpable abnormality or worrisome radiographic abnormality persists in the neck 8-9 weeks after completion of therapy. A neck dissection is optional for patients with multiple positive lymph nodes or with lymph nodes exceeding 3 cm in diameter at pre-treatment (N2a, N2b, N3) who achieve a complete clinical and radiographic response in the neck. All patients will be assessed at approximately 8 weeks post-treatment with CT scan or MRI by the same technique used at baseline.
Study: NCT01206335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OHR/AVR118
Description: OHR/AVR118 given subcutaneously at 4mL per day
Study: NCT01506739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil Hydrochloride
Description: Drug E2020 film-coated tablet: E2020 film-coated tablet (5mg) orally administered in a single dose with 200 mL water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil Hydrochloride
Description: Drug E2020 dry syrup 1% form (suspended): E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose after suspended in 20 ml water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil Hydrochloride
Description: Drug E2020 dry syrup 1% form: E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose with 200 mL water.
Study: NCT02357836

Intervention type: DRUG
Group type: OTHER
Intervention: Itraconazole
Description: Once on study, itraconazole will be taken twice daily for a total of 10-14 days. After being on itraconazole for 7-10 days, Post-treatment assessments will include a skin biopsy, blood draw for the PK (pharmacokinetics) analyses and the cytokine panel, and also MRI evaluations (anticipated to last 45-50 minutes). Toxicity assessments and laboratory checks will also be conducted during that time. Following these assessments, itraconazole will be continued until the day of surgery. At the time of surgical resection, a tissue sample (with adjacent normal tissue as per standard resection technique) will be obtained to complete the analysis. Following resection, subjects will be followed per standard post-operative procedure.
Study: NCT00752375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim Sulfamethoxazole
Description: * Children \>3months of age will receive Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)per day for one year.~* Children under 3 months of age will receive amoxicillin 10mg/kg once per day for one year.~* Those children with a Sulfa allergy will receive nitrofurantoin (1mg/kg) once per day for one year.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: * Placebo matching Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)for children more than 3 months of age~* Placebo matching amoxicillin 10mg/kg once per day for children under 3 months of age~* Placebo matching nitrofurantoin (1mg/kg) once per day for children with a sulfa allergy.
Study: NCT03397212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NADA acupuncture
Description: Ear acupuncture protocol described by National Acupuncture Detoxification Association

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Ear acupuncture using inactive sham points
Study: NCT00360971

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: neck dissection
Description: A neck dissection is required for patients with persistent nodal disease, any stage, if a palpable abnormality or worrisome radiographic abnormality persists in the neck 8-9 weeks after completion of therapy. A neck dissection is optional for patients with multiple positive lymph nodes or with lymph nodes exceeding 3 cm in diameter at pre-treatment (N2a, N2b, N3) who achieve a complete clinical and radiographic response in the neck. All patients will be assessed at approximately 8 weeks post-treatment with CT scan or MRI by the same technique used at baseline.
Study: NCT04050592

Intervention type: DRUG
Group type: OTHER
Intervention: Estradiol
Description: Active intervention is estradiol. Hormone therapy (HT) of all 150 participants will be standardized to 2.0 mg of oral estradiol (E2) without progestogen for six weeks prior to randomization. After that participants will be randomized into three groups (A, B, C) of equal size.

Intervention type: DRUG
Group type: OTHER
Intervention: Estradiol
Description: Active intervention is estradiol. Hormone therapy (HT) of all 150 participants will be standardized to 2.0 mg of oral estradiol (E2) without progestogen for six weeks prior to randomization. After that participants will be randomized into three groups (A, B, C) of equal size.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: Active intervention is estradiol. Hormone therapy (HT) of all 150 participants will be standardized to 2.0 mg of oral estradiol (E2) without progestogen for six weeks prior to randomization. After that participants will be randomized into three groups (A, B, C) of equal size.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Those in groups A and B will switch from estradiol to placebo at the beginning of the 10th week after abrupt or tapered discontinuation of HT.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Those in groups A and B will switch from estradiol to placebo at the beginning of the 10th week after abrupt or tapered discontinuation of HT.
Study: NCT01205685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: In a pill form by mouth, twice a day (12 hours apart)~During the safety run portion of the study~* Dose level 2 = 150 mg twice a day~* Dose level 1 = 100 mg twice a day~* Dose level -1 = 100 mg twice a day~* Dose level -2 = 100 mg twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: During the safety run phase of the study:~* Dose Level 2 = 100 mg/d~* Dose Level 1 = 100 mg/d~* Dose Level -1= 75 mg/d~* Dose Level -2 = 50 mg/d
Study: NCT00360971

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: A radiation dose of 70 Gy with at least 66 Gy to at least 2 mucosal sites of the oral cavity/oropharynx mucosa. Radiation therapy can be given with 3D conformal (3D-CRT) or with intensity modulated RT (IMRT) techniques; however, the chosen modality must be used for the entire course of treatment.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiation therapy
Description: A radiation dose of 70 Gy with at least 66 Gy to at least 2 mucosal sites of the oral cavity/oropharynx mucosa. Radiation therapy can be given with 3D conformal (3D-CRT) or with intensity modulated RT (IMRT) techniques; however, the chosen modality must be used for the entire course of treatment.
Study: NCT03623100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Production Treatment.
Description: Speech production treatment will be delivered in two phases: Imitation and Spontaneous Production. Treatment will be provided two times weekly in 1-hour sessions, for up to 19 sessions. Every child's intervention program will target a single phoneme that was excluded from his or her phonemic inventory. Each treatment phoneme will be targeted through the production of five words that will be initially introduced to the child using a storybook reading format. Imitation treatment will continue until a child maintains 75% accurate production of the treated phoneme over two consecutive sessions (i.e. performance-based criterion) or until seven consecutive sessions are completed (i.e. time-based criterion). Spontaneous Production will continue until the child maintains either a performance-based criterion of 90% accurate production of the treated phoneme over 3 consecutive sessions, or a time-based criterion of 12 consecutive sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Production + Speech Perception Treatment.
Description: This speech treatment condition will be administered in the same way as the Speech Production treatment. The difference in conditions will be that speech treatment in this condition will last for 50 minutes rather than 60 minutes. The remaining 10 minutes of each session will involve the speech perception training. These speech perception tasks will involve previously recorded word-level productions focusing on the same phoneme that is addressed in speech production treatment in word-initial position. A variety of words produced correctly and incorrectly by adults and children will be presented in pairs and the children will have to determine if the words contain the same word-initial phoneme or two different phonemes.
Study: NCT02819271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXL-1427 Ascending Dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXL-1427 Descending Dose
Study: NCT02200016

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided short axis (SAX) placement of sciatic nerve catheters
Description: Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the short axis of the sciatic nerve behind the knee.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided long axis (LAX) placement of sciatic nerve catheters
Description: Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the long axis of the sciatic nerve behind the knee.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B Braun Contiplex S catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B Braun Contiplex S catheter
Study: NCT03959735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Description: HIIT is a type of exercise involving alternating short bursts of high intensity exercise with recovery periods of rest or light exercise.
Study: NCT05753358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total Worker Health for Wildland Firefighters
Description: The program is structured as 30-minute modules that can be done individually, with a partner, as a group or in a classroom setting. The six core modules are supplemented with eight elective modules. The program can be accessed on a smartphone, tablet or computer, and if needed can be downloaded as a pdf.
Study: NCT01527500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFG316
Description: LFG316 5 mg/50 μL solution for IVT injection,

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham injection (akin to intravitreal injection but without intravitreal needle; no investigational drug given)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFG316 Lower dose
Description: LFG316 5 mg/50 μL solution for IVT Injection